Signet Therapeutics' Lead Candidate SIGX1094 Wins VB-100 'Best Biotech Innovation Product' Award

Last Friday evening, Vascular Network unveiled the 9th Future Healthcare 100 list (VB-100) with great fanfare, featuring SIGNET's core pipeline.SIGX1094 Honored as "Best Biotechnology Innovation Product"Award.

SIGX1094 is the world’s first targeted drug for diffuse gastric cancer independently developed by Signet Therapeutics. It is the first drug developed based on an organoid and AI technology platform and also the world’s first FAK/SRC dual-target inhibitor to enter the clinical stage.FAK and its key binding factor SRC form a complex to activate downstream pathways. During the drug development process, the inhibition of either FAK or SRC alone may lead to compensatory effects from the other, significantly reducing the anti-tumor efficacy of the drug. Therefore, by simultaneously blocking the key signaling pathways of both FAK and SRC, the limitations of single-target inhibitors are overcome. SIGNET, relying on its self-developed organoid disease model platform for target validation and efficacy evaluation, integrates AI-driven drug design from XtalPi (2228.HK). Within just four years, SIGNET has developed SIGX1094, the world’s first targeted drug for diffuse gastric cancer, which has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA.

The Future Healthcare 100 List, established in 2015, aims to precisely select innovative healthcare players in China that truly represent the future direction of healthcare. It seeks to uncover the core driving forces of China’s future healthcare industry, thereby effectively promoting the innovation and transformation process of the healthcare industry. After years of development and refinement, this list has become a highly authoritative and influential benchmark in the healthcare industry, receiving significant attention and recognition from numerous investment institutions and enterprises. The selection process is rigorous and comprehensive, based on the VB100 Value Assessment Model. It involves multiple stringent screening stages, including self-submission by companies, review by the VB100 Evaluation Committee, cross-review by supporting organizations, and final review by the Expert Committee. The evaluation comprehensively considers companies’ strengths and potential across various dimensions such as human resources, knowledge resources, key partner resources, and market performance, ultimately selecting top performers in each field.

SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a National High-tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since completed nearly 220 million yuan in financing and project funding. Currently, the company has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted therapy for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China's NMPA, along with Orphan Drug Designation and Fast Track Designation from the U.S. FDA. Phase I clinical trials are currently underway at Peking University Cancer Hospital.

Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Full of Hope, Studying Things to Gain Knowledge." The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and new target discovery. Combining AI-driven screening, synthesis, and optimization of small molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has approximately 1500㎡ of R&D space and 500㎡ of animal laboratory space. Signet Therapeutics’ organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.